Superior Efficacy of the Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor Prifemilast Versus Apremilast in Moderate to Severe Plaque Psoriasis: Top-Line Results of a Head-to-Head Phase 3 Trial

Conclusion

• Prifemilast demonstrated superior efficacy to apremilast in reducing the extent and severity of psoriasis and was well tolerated
• These findings support continued development of prifemilast for psoriasis and other IMIDs, including ulcerative colitis and Crohn’s disease

Authors

Lin Cai, Guoqiang Zhang, Lihua Wang, Hui Xu, Xinsuo Duan, Litao Zhang, Xiaoyong Zhou, Huiming Zeng, Ningning Dang, Jianyun Lu, Liming Wu, Aihua Wei, Qinghua Zhu, Qian Zhu, Weifen Zhou, Jianzhong Zhang

Citation

Cai L, et al. Superior Efficacy of the Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor Prifemilast Versus Apremilast in Moderate to Severe Plaque Psoriasis: Top-Line Results of a Head-to-Head Phase 3 Trial. Poster presented at: 26th Annual Fall Clinical Dermatology Conference; October 8–11, 2026; Las Vegas, NV. ClinicalTrials.gov: NCT07712731.

Prifemilast is an investigational agent and is not approved for use by any regulatory authority.